Analytical Data
-
Gene name
MAP1LC3A
- Application
-
Alternative Names
MAP1ALC3; MAP1BLC3; LC3; LC3A; ATG8E; Autophagy-related ubiquitin-like modifier LC3 A; MAP1 light chain 3-like protein 1
-
Species
Human
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 95% as determined by SDS-PAGE.
-
Uniprot
Q9H492
-
Expression Region
Met1~Gly120
-
Molecular Weight
20kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
MAP1LC3A, or Microtubule-associated protein 1 light chain 3 alpha, is a critical protein involved in the autophagy process, which is essential for cellular homeostasis and recycling of cellular components. Research on MAP1LC3A has gained prominence due to its role in various physiological and pathological processes, including cancer, neurodegenerative diseases, and infections. As a key regulator of autophagy, MAP1LC3A is involved in the formation of autophagosomes and interacts with other proteins to facilitate the degradation of damaged organelles and misfolded proteins. Over the years, scientists have focused on characterizing MAP1LC3A and its potential as a therapeutic target, especially in cancer treatments where autophagy can influence tumor growth and resistance to chemotherapy. Studies have demonstrated that altered expression levels of MAP1LC3A can affect cell survival and proliferation, making it a significant molecule for understanding the underlying mechanisms of various diseases. Moreover, developing recombinant MAP1LC3A proteins has opened avenues for detailed structural and functional studies, enabling researchers to explore its interactions and regulatory mechanisms further. This research not only contributes to basic biology but may also have implications in developing novel therapeutic strategies targeting autophagic pathways in diseases marked by dysfunctional autophagy.
